A phase I trial (NCT01837095) with CXCR4 antagonist Balixafortide and Eribulin chemotherapy evaluated the safety, tolerability, pharmacokinetics and efficacy in heavily pretreated, relapsed breast cancer patients. This evidence concerns the gene CXCR4 and breast carcinoma.